Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 5/20 | 0.78 |
| ▸ | IGF1R | P08069 | 4/20 | 0.75 |
| ▸ | INSR | P06213 | 2/20 | 0.75 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.68 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.65 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | CDC25B | P30305 | 1/20 | 0.63 |
| ▸ | NAT1 | P18440 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125789 | 1.00 | PIK3CG (0.78) | PIK3CGIGF1RINSRPTP4A3HSPD1 | |
| SCHEMBL3125785 | 1.00 | PIK3CG (0.78) | PIK3CGIGF1RINSRPTP4A3HSPD1 | |
| SCHEMBL4200323 | 0.87 | PIK3CG (1.00) | PIK3CGIGF1RINSRPOLBMEN1 | |
| SCHEMBL1064039 | 0.87 | PIK3CG (1.00) | PIK3CGIGF1RINSRPOLBMEN1 | |
| SCHEMBL1064036 | 0.87 | PIK3CG (1.00) | PIK3CGIGF1RINSRPOLBMEN1 | |
| SCHEMBL13388762 | 0.86 | IGF1R (0.72) | PIK3CGIGF1RINSRPTP4A3HSPD1 | |
| SCHEMBL3904132 | 0.86 | IGF1R (0.72) | PIK3CGIGF1RINSRPTP4A3HSPD1 | |
| SCHEMBL6389114 | 0.86 | PIK3CG (0.79) | PIK3CGIGF1RINSRPTP4A3HSPD1 | |
| SCHEMBL3897382 | 0.86 | IGF1R (0.79) | PIK3CGIGF1RINSRPTP4A3HSPD1 | |
| SCHEMBL6089724 | 0.86 | IGF1R (0.72) | PIK3CGIGF1RINSRPTP4A3HSPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120219613-A1 | Novel Antiviral Agents for Enveloped Viruses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-08-30 | — | — | US | claimed |
| WO-2005041951-A2 | RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-20200268768-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | TOBIRA THERAPEUTICS INC (US) | 2020-08-27 | — | — | US | disclosed |
| US-20180360846-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | TOBIRA THERAPEUTICS, INC. (US) | 2018-12-20 | — | — | US | disclosed |
| EP-3349751-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | Tobira Therapeutics, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017048322-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | TOBIRA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20120219613-A1 | Novel Antiviral Agents for Enveloped Viruses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-08-30 | — | — | US | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| WO-2010148351-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180360846-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | CCR2, CCR5, CCR1 | PIK3CG 3034/4885IGF1R 891/4885INSR 930/4885 |
| US-20200268768-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | CCR2, CCR5, CCR1 | PIK3CG 3022/4885IGF1R 931/4885INSR 950/4885 |
| US-20120219613-A1 | Novel Antiviral Agents for Enveloped Viruses | MAVS, LAMP1, HAVCR2 | PIK3CG 4355/4885IGF1R 3107/4885INSR 3037/4885 |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM2, PIM1, CDK2 | PIK3CG 456/4885IGF1R 522/4885INSR 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.